Mounjaro injection (tirzepatide): effect, dosing and the study data

By the Doktorly editorial team · Medically reviewed by the Doktorly medical team · Last updated: 10 November 2026

Mounjaro is the newest addition to the weight-loss injections – and the most effective one in the studies to date. The difference: while Ozempic and Wegovy mimic a single hormone, Mounjaro activates two distinct signalling pathways at the same time.

What that means medically, how the dosing schedule is structured and where Mounjaro stands in direct comparisons – all of that is covered here.

Dual mechanism: GLP-1 plus GIP

Mounjaro contains the active ingredient tirzepatide from Eli Lilly. It is what is known as a dual agonist: it acts on both the GLP-1 and the GIP hormone receptors. Both pathways are involved in appetite regulation, satiety and fat metabolism. In practice, this means hunger and food cravings drop noticeably more strongly for many users than with GLP-1-only injections.

Approval: diabetes first, weight management after

The EMA approved Mounjaro for type 2 diabetes in 2022; at the end of 2023 the approval for weight management in adults with obesity or overweight plus a weight-related condition followed. In Germany the injection has been broadly available since 2025 – for both indications.

Dosage: building up to 15 mg

  1. 2.5 mg weekly (4 weeks – start-up dose only)
  2. 5.0 mg weekly (at least 4 weeks)
  3. If needed: 10 mg weekly
  4. Maximum: 15 mg weekly

The injection is given once a week, ideally on the same weekday. Injection sites (abdomen, thigh, upper arm) should be rotated.

Study data: the strongest weight-loss figures on the market

In the pivotal trial SURMOUNT-1, participants on the highest dose (15 mg) lost on average about 20.9 % of their body weight over 72 weeks – placebo: around 3 %. NEJM: SURMOUNT-1 (2022).

Particularly interesting is the head-to-head comparison SURMOUNT-5: tirzepatide 15 mg achieved roughly 20 % weight loss versus roughly 14 % on semaglutide 2.4 mg (Wegovy). NEJM: SURMOUNT-5 (2025). Efficacy is not everything, though – tolerability and your individual situation matter just as much.

Costs

Depending on the dose, self-payer costs are roughly 350–450 € per month. Higher doses cost more than the entry steps. Insurance reimbursement is currently the exception and has to be clarified individually.

Side effects

Who is Mounjaro suitable for?

Mounjaro is an option for adults with BMI ≥ 30 or BMI ≥ 27 plus a weight-related condition – particularly when experience with other GLP-1 injections already exists or the weight-loss target is high. The decision rests with the medical team after reviewing your history. An overview of all alternatives is available in our comparison of weight-loss injections.

Frequently asked questions about Mounjaro

Frequently asked questions

Mounjaro or Wegovy – which is stronger?

In the head-to-head trial (SURMOUNT-5), tirzepatide achieved higher weight losses than semaglutide 2.4 mg. "Stronger" does not automatically mean better suited – tolerability and individual factors count as well.

How quickly does Mounjaro work?

Many users notice reduced hunger already in the start-up phase. Significant weight changes usually appear from week 4–8.

What is the difference between Mounjaro and Zepbound?

Zepbound is the US brand name of the same active ingredient, tirzepatide, for the weight-loss indication. In the EU the product is called Mounjaro.

Does the injection always have to be on the same day?

Keeping the same weekday is recommended. If a dose is shifted, at least three days (72 hours) must pass between two doses.

Sources